MARKET

IMMU

IMMU

Immunomedics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.14
-3.34
-24.78%
Closed 19:58 04/01 EDT
OPEN
10.86
PREV CLOSE
13.48
HIGH
11.50
LOW
9.45
VOLUME
17.47M
TURNOVER
--
52 WEEK HIGH
22.22
52 WEEK LOW
9.18
MARKET CAP
2.17B
P/E (TTM)
-5.5013
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMMU stock price target is 26.09 with a high estimate of 40.00 and a low estimate of 16.00.

EPS

IMMU News

More
  • From the best new restaurant in America to being closed
  • CNBC.com · 8h ago
  • In her own words: A deli owner in Clearwater, Fla.
  • CNBC.com · 8h ago
  • From the ICU front lines in Chicago
  • CNBC.com · 9h ago
  • This is not a panic moment: Investment pro
  • CNBC.com · 9h ago

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About IMMU

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.
More

Webull offers kinds of Immunomedics, Inc. stock information, including NASDAQ:IMMU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMU stock news, and many more online research tools to help you make informed decisions.